See Beyond the Lumen
Deliver personalized patient care with the only histologically-validated, objective and quantitative CTA-based arterial analysis software.
Clinical Problem
Misdiagnosed Myocardial Ischemia, Heart Attack & Stroke Risk Leads to Poor Outcomes
Myocardial ischemia occurs when blood flow to your heart is reduced, preventing the heart muscle from receiving enough oxygen. This is often the result of plaque buildup inside the artery wall.
Heart attack and stroke are primarily caused by non-obstructive, but unstable plaque in the arteries that goes undiagnosed and untreated.1 Current non-invasive testing cannot visualize the biology deep inside artery walls where heart disease develops.
Elucid is harnessing scientific imaging and histology to help enable quick, accurate, noninvasive diagnoses and precise treatment of cardiovascular disease to enable better patient outcomes.
Solution
PlaqueIQ™ Technology
Accurate Clinical Insights Based on Biology
Introducing the first and only non-invasive image analysis software that employs CT angiography and patented computer algorithms, based on expert histologic examination of thousands of tissue samples and images, to objectively quantify the extent and stability of arterial plaque for tailored patient care.
Technology backed by 40+ years of clinical research
Powerful. Precise. Proven.
87%
Accurate prediction of major adverse cardiac events2*
40%
Better Stroke Prediction3*
Elucid PlaqueIQ Comprehensive
Healthcare Solutions
- Assess plaque composition with histology-validated software
- Quantify plaque to inform heart attack and stroke risk with greater accuracy
- Visualize a comprehensive and objective view of arterial disease to enable personalized treatment plans before a patient ever enters the hospital
- Understand your risk of heart attack and stroke
- Receive safe and accurate non-invasive diagnostic testing
- Experience personalized treatment plans
- Early detection for improved clinical care and consistent outcomes
- Reduce unnecessary invasive testing, lowering cost of care
- Enables physicians to identify asymptomatic high-risk patients who may have otherwise gone untreated
- Help identify promising drug candidates with greater speed and accuracy
- May reduce clinical trial size, costs and timelines by stratifying high-risk patients
- If you are interested in submitting a proposal for a research study, click here.
PlaqueIQ™ Technology
Translate CTA into Scientific Images in 2 Steps
Accurately restore vessel structure and plaque morphology, including lipid rich necrotic core:
Image Processing
The only CTA-based plaque assessment rigorously validated with histopathology*
Based on expert analysis of microscopic tissue samples by world-renowned cardiovascular pathologists.
- Lipid-Rich Necrotic Core
- Calcification
- Intraplaque Hemorrhage*
- Matrix
- Fibrous Cap/Perivascular Adipose Tissue*
*Available in Elucid PlaqueIQ Research Edition only.
In partnership with:
The Elucid algorithms demonstrate excellent correlation and are highly accurate for tissue characterization when compared to ex vivo histopathology.”
Secure, Workflow-Oriented Technology
News
Elucid Receives U.S. 510(k) Clearance of PlaqueIQ™ Image Analysis Software to Aid Cardiovascular Disease Assessment
First and Only Software Validated on Ground-Truth Histology, the Gold Standard for Plaque Characterization BOSTON, Oct. 1, 2024 – Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis...
Elucid Names Kelly Huang as CEO
Experienced commercial leader takes helm to expand cardiovascular diagnostic company globally and commercialize company’s flagship plaque analysis software BOSTON, July 22, 2024 – Elucid, a pioneering AI medical technology company providing physicians with imaging...
Elucid Commences International PRE-VUE CCT Registry Study
Multi-center, Retrospective Trial to Assess Prognostic Accuracy of Elucid’s Plaque and Plaque-based FFRCT Software in Patients with Clinically Indicated CCTA SCCT2024, WASHINGTON, D.C., and BOSTON, July 18, 2024 – Elucid, a pioneering AI medical technology company...
About
Bringing Imaging to Life™
Our mission is to provide comprehensive and accurate clinical insights based on ground-truth histology, enabling unprecedented precision healthcare for vascular disease. Contact us today to learn more about ElucidVivo clinical solutions:
Our Portfolio
Elucid PlaqueIQ
FDA-cleared, non-invasive CTA analysis software providing unprecedented specificity of plaque stability and vessel structure, based on histology.
Elucid FFRCT + PlaqueIQ
Combination of plaque analysis, based on histology, and FFR for a more direct measure of stress induced ischemia while characterizing plaque risk. Coming Soon!
ElucidVivo™ Clinical Research
CTA analysis software with innovative additional features for clinical research and studies.
ElucidVivo is used to help evaluate patient outcomes, safety and clinical efficacy in clinical trials with industry partners, including:
Contact
Contact us today to learn more about ElucidVivo or to schedule a product demo.
Boston, MA 02116